The DOI matches its Crossref record; 96 of the 97 references it cites were found in a registry or an index; 20 of the 98 sources its claims cite were checked for support.
Light therapy for bipolar disorders: Clinical recommendations from the international society for bipolar disorders (ISBD) Chronobiology and Chronotherapy Task Force
Open accessAbstract
The International Society for Bipolar Disorders (ISBD) Chronobiology and Chronotherapy Task Force conducted a comprehensive review to deliver concise evidence-based recommendations on the use of bright light therapy (BLT) for bipolar disorder (BD). Adjunctive BLT is likely an efficacious acute treatment for bipolar depression as implicated by higher quality evidence. The position of maintenance BLT for relapse prevention awaits further investigation. Protocols of effective BLT in BD are similar to parameters indicated for treatment of seasonal and non-seasonal major depressive disorder. Anti-manic prophylaxis (especially for BD-I) and clinical monitoring are recommended with initiation of and ongoing light treatment. Administer BLT daily, preferably in the morning or at mid-day. If mornings are prohibitive, then mid-day exposure, implemented to avoid excessively early wake times, is an acceptable alternative. Informed by the literature, target 30 min/day of BLT exposure. Patients wary of emergent hypomania or partial responders, can initiate 15 min/day and increase by 15 min each week to full response (or 30-60 min/day by the fourth week). Consider patient centred outcome assessments to evaluate mood response, safety and side effects. Clinical improvement is typically observed within 1-2 weeks, with response/remission expected by 4-6 weeks. Integration of BLT with other chronotherapeutic strategies may enhance long-term efficacy.
Overview
CoChat Summary
TL;DR
This ISBD Task Force evidence-based practice guideline concludes adjunctive bright light therapy (BLT) is likely efficacious for acute bipolar depression, with protocols similar to those used in seasonal and non-seasonal major depressive disorder. It provides step-by-step clinical recommendations on dosing, timing, safety monitoring, anti-manic prophylaxis, and implementation, while noting that maintenance evidence and long-term RCTs in bipolar disorder are lacking.
Key findings
- Adjunctive BLT is likely an efficacious acute treatment for bipolar depression. In meta-analyses cited, Lam et al. found significant improvement in clinician-rated depressive symptoms (HDRS SMD = 0.43; p = 0.03) and clinical response favouring BLT (OR = 2.32; p = 0.024); Geoffroy et al. found combination BLT plus antidepressant superior to monotherapy (SMD = 0.56; p < 0.001), with no significant difference between BLT and drug alone (SMD = 0.19; p = 0.17).
- Recommended acute protocol: bright, white, UV-filtered light at 5,000–10,000 lux, 30–33 cm from the eyes; daily morning (7:00–9:00 AM) or mid-day (12:00–2:30 PM) exposure; target 30 min/day, with an option to start at 15 min/day and increase by 15 min weekly to 30–60 min/day by week 4. Clinical improvement is typically seen within 1–2 weeks, with response/remission expected by 4–6 weeks.
- Anti-manic prophylaxis is recommended especially for BD-I, with an adequate mood stabiliser for at least 2–4 weeks before initiating BLT and during treatment. In the LuBi trial cited, 2/34 participants (6%) experienced a hypomanic switch, 5/34 (15%) had subsyndromic hypomanic symptoms, and overall 7/34 (20.6%) exhibited either subsyndromic or full-blown hypomania; all symptoms resolved within 3 days after dose reduction.
- Maintenance BLT for relapse prevention awaits further investigation. The paper notes no longer-term follow-up RCTs of BLT in BD; expert consensus recommends continuing BLT until full episode recovery and maintaining for 1 year, with many patients possibly able to reduce intensity or duration.
Methods
- Design: ISBD Chronobiology and Chronotherapy Task Force comprehensive review and evidence-based practice guideline, including a brief narrative review of efficacy studies and clinical recommendations.
- Data: published literature on BLT in bipolar disorder, major depressive disorder, and seasonal affective disorder, including RCTs and meta-analyses; the LuBi dose-escalation phase 1/2 randomised double-blind trial (n = 34) is cited for hypomanic switch rates. No new primary data were collected.
- Analysis: narrative synthesis and consensus recommendations, with protocol tables (Tables 1–2) and a clinical algorithm.
Limitations
- The paper states that varying light treatment parameters, small sample sizes, brief durations of therapy, and inconsistent quality across trials may limit generalisability; maintenance BLT for relapse prevention awaits further investigation, and there are no longer-term follow-up RCTs of BLT in BD.
- The paper states that LuBi observations were limited by sample size, that there is a disproportionate lack of human data from light studies, and that feasibility/implementation barriers include cost, lack of reimbursement, suboptimal adherence, device standardisation, and access issues in low- and middle-income countries.
- Evident from the text: many recommendations rely on expert consensus and indirect evidence from SAD/MDD, and some parameters—such as optimal timing and light source spectra for non-seasonal bipolar depression—are not fully standardised.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
17 Valid · 1 Not valid · 47 Not checked · 14 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“although usage parameters are not yet fully standardised (Geoffroy et al. 2018).”
§ Light therapy for bipolar disorders: Clinical recommendations from the international society for bipolar disorders (ISBD) Chronobiology and Chronotherapy Task Force > How to use/implement BLT > Treatment parameters: Basic protocols and directions for acute treatment
What the sources say
- Supportedcites Geoffroy et al. 2018 source
The Background (page unavailable) says that BLT administration characteristics—including duration, dose escalation, and morning versus mid-day exposure—are not codified for non-seasonal bipolar depression. The Methods (page unavailable) describe the study’s use of low-intensity, blue-enriched light, so the claim is supported in that clinical context. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The antidepressant effect was achieved even when low (<5000 lux) light intensity was used (Dallaspezia and Benedetti 2020; Wang et al. 2020)”
§ Light therapy for bipolar disorders: Clinical recommendations from the international society for bipolar disorders (ISBD) Chronobiology and Chronotherapy Task Force > How to use/implement BLT > Treatment parameters: Basic protocols and directions for acute treatment
What the sources say
- Not checked — no full text of the sourcecites Dallaspezia and Benedetti 2020 source
- Supportedcites Wang et al. 2020 source
The Results subsection on light intensity reports that low-intensity light reduced depression severity, and labels Fig. 14 as using intensities below 5000 lux. The Discussion cautions that this finding was based on only two cohort studies and requires confirmation. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The superiority of blue light boxes compared to bright white light for treatment of bipolar depression has not been established (Gallin et al. 1995; Brouwer et al. 2017).”
§ Light therapy for bipolar disorders: Clinical recommendations from the international society for bipolar disorders (ISBD) Chronobiology and Chronotherapy Task Force > How to use/implement BLT > Side effects and safety
What the sources say
- Not checked — no full text of the sourcecites Gallin et al. 1995 source
- Could not verifycites Brouwer et al. 2017 sourceExperimental — accuracy not yet measured
The available Abstract discusses the ocular safety of light therapy, not whether blue light boxes are more effective than bright white light for bipolar depression. Searches for that comparison and for treatment efficacy returned no passage addressing it. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Symptomatic remission should be expected by four to six weeks of treatment (Sit et al. 2018; Lam et al. 2020).”
§ Light therapy for bipolar disorders: Clinical recommendations from the international society for bipolar disorders (ISBD) Chronobiology and Chronotherapy Task Force > How to use/implement BLT > Time course of effects for acute BLT
What the sources say
- Partly supportedcites Sit et al. 2018 sourceExperimental — accuracy not yet measured
The Results passage reports remission in 68.2% of patients receiving adjunctive bright light therapy for bipolar depression during weeks 4–6, and the Discussion says its large effect emerged in that period. This supports the timing for that treatment and population, but not a general expectation of remission by four to six weeks of treatment. (LLM, conf=0.83)
- Partly supportedcites Lam et al. 2020 sourceExperimental — accuracy not yet measured
The Secondary Outcomes section reports clinical remission in 40.7% of patients receiving active light therapy, but the overall remission difference from controls was not statistically significant. The Discussion says follow-up was generally short, with only two studies using 6–8 weeks; it does not establish that remission should be expected by four to six weeks. Page numbers are unavailable in our copy. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Continued improvement can be observed after six weeks of treatment (see dose-response relationship; (Sit et al. 2018)).”
§ Light therapy for bipolar disorders: Clinical recommendations from the international society for bipolar disorders (ISBD) Chronobiology and Chronotherapy Task Force > How to use/implement BLT > Continuation of treatment
What the sources say
- Partly supportedcites Sit et al. 2018 sourceExperimental — accuracy not yet measured
The Discussion reports a large treatment effect between weeks 4 and 6 and suggests that a longer protocol might yield further improvement. It does not report observing continued improvement beyond six weeks; that is an extrapolation from the remission-rate trajectory. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
42 more claims · 4 with their cited sources checked
Create a free account to see all 79 claims and to verify the 3 references still open.
- Probably not a substantial claim. 8
- It may state two separate claims as one. 28
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Light therapy for bipolar disorders: Clinical recommendations from the international society for bipolar disorders (ISBD) Chronobiology and Chronotherapy Task Force > Summary of key take-home messages and step-by-step guide for the use of BLT
“Certain remitted patients may prefer to continue BLT to prevent recurrence for up to one year”
§ Light therapy for bipolar disorders: Clinical recommendations from the international society for bipolar disorders (ISBD) Chronobiology and Chronotherapy Task Force > How to use/implement BLT > Continuation of treatment
“certain remitted BLT patients may decide to continue BLT for at least (and possibly beyond) one year as a preventive measure against recurrence”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Light therapy for bipolar disorders: Clinical recommendations from the international society for bipolar disorders (ISBD) Chronobiology and Chronotherapy Task Force > Brief, narrative review of efficacy studies of BLT
“Similar results were found in subsequent meta-analyses (Franken et al. 1991; Dijk and Czeisler 1995; Brainard et al. 2001).”
§ Light therapy for bipolar disorders: Clinical recommendations from the international society for bipolar disorders (ISBD) Chronobiology and Chronotherapy Task Force > References
“26. Franken P, Tobler I, Borbély AA. 1991. Sleep homeostasis in the rat: simulation of the time course of EEG slow-wave activity.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Light therapy for bipolar disorders: Clinical recommendations from the international society for bipolar disorders (ISBD) Chronobiology and Chronotherapy Task Force > How to use/implement BLT > Light devices
“The ideal dimensions of a portable unit should measure at least 30 cm (12 inches) in height by 35 cm (14 inches) in length”
§ Light therapy for bipolar disorders: Clinical recommendations from the international society for bipolar disorders (ISBD) Chronobiology and Chronotherapy Task Force > Summary of key take-home messages and step-by-step guide for the use of BLT
“The dimension of the ideal unit measures a minimum of 30 cm (12 inches) in height by 36 cm (14 inches) in length”
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910 · cited 1×
“…effects (Ballard et al. 2024) and to inform decisions on individual dosing needs. the self-reported, 9-item Patient Health Questionnaire (PHQ-9, (Kroenke et al. 2001)), 7-item generalised anxiety disorder scale (GAD-7, (Spitzer et al. 2006)) and the clinician rating instruments, such as the…”
A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7
Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.10.1092 · Cited by 31,765
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 4×
“…regular monitoring and follow up appointments that are enhanced with self-reported or clinician-administered measures to assess patient-centred outcomes and to identify early warning signs of mood worsening or recurrence (Young et al. 1978; Sit et al. 2018; Sit and Haigh 2019; Pulido et al. 2025).”
InfluentialPosner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 1×
“…utilise patient centred outcome assessments to evaluate mood severity, safety including suicidal risk (https://www.cssrs. columbia.edu, (Posner et al. 2011)), and side effects (Ballard et al. 2024) and to inform decisions on individual dosing needs. the self-reported, 9-item Patient…”
Two-Process Model of Sleep Regulation
(2009) · Encyclopedia of Neuroscience · doi:10.1007/978-3-540-29678-2_6166 · Cited by 3,899
Dibner, C., Schibler, U., & Albrecht, U. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135821 · Cited by 2,421
Rosenthal, N. E. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1984.01790120076010 · Cited by 2,385
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Stephan, F. K., & Zucker, I. (1972) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.69.6.1583 · Cited by 2,039
Action Spectrum for Melatonin Regulation in Humans: Evidence for a Novel Circadian Photoreceptor
Brainard, G. C., Hanifin, J. P., Greeson, J. M., Byrne, B., Glickman, G., Gerner, E., & Rollag, M. D. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-16-06405.2001 · Cited by 1,930
Research works printed but not linked: 2
- 10.1111/bdi.13018 · DOI · Paper page
- Williams JBW, Terman M. 2003. Structured interview guide for the Hamilton Depression Rating Scale with atypical depression supplement (SIGH-ADS). New York NY: New York State Psychiatric Institute.
Cited by
Clinical approaches to hypersomnolence complaints in psychiatry: A narrative review
Geoffroy, P. A., Christodoulou, N., Micoulaud‐Franchi, J., & Maruani, J. (2026) · L Encéphale · doi:10.1016/j.encep.2026.03.002 · Cited by 7
Self-citationCircadian-Related Hypothalamic Structure Differs by Chronotype in Bipolar Disorder
Tahedl, M., Rohrer, J., Seifritz, E., Smith, D. J., & Homan, P. (2026) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2026.04.003 · Cited by 2
Self-citationMehrdadi, I., Kuster, S., Rohrer, J., Seifritz, E., Chatelain, C., Chan, G., Homan, P., & Tahedl, M. (2026) · medRxiv · doi:10.64898/2026.09.24.26363889
Bipolare Störungen: Was gibt es Neues in der Therapie?
Bauer, M. (2026) · DNP – Die Neurologie & Psychiatrie · doi:10.1007/s15202-026-6776-y
Micoulaud‐Franchi, J., Maruani, J., Lambert, I., Peter‐Derex, L., Yrondi, A., Baillieul, S., Trzépizur, W., Masset, L., Mauries, S., Quilès, C., et al. (2026) · L Encéphale · doi:10.1016/j.encep.2026.08.002
Self-citation
Metadata
- Authors
- Geoffroy, P. A., Palagini, L., Henriksen, T. E. G., Bourgin, P., Garbazza, C., Gronfier, C., Esaki, Y., Fernandez, D. C., Lam, R. W., Lee, H.-J., Lejoyeux, M., Maruani, J., Martiny, K., Murray, G., Riemersma-Van Der Lek, R. F., Ritter, P., Schulte, P. F. J., Smith, D. J., Terman, M., Zeitzer, J. M., & Sit, D. K.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- University of Pisa (IT)
- Fonna Hospital Trust (NO)
- Universitäre Psychiatrische Kliniken Basel (CH)
- Lyon 1 Université (FR)
- Fujita Health University (JP)
- Cincinnati Children's Hospital Medical Center (US)
- University of British Columbia (CA)
- Korea University (KR)
- Inserm (FR)
- University of Copenhagen (DK)
- Swinburne University of Technology (AU)
- Mental Health Services Drenthe
- University Hospital Carl Gustav Carus (DE)
- GGZ Noord-Holland-Noord (NL)
- University of Edinburgh (GB)
- Columbia University (US)
- Stanford Medicine (US)
- Northwestern University (US)
- Corresponding author
- Geoffroy, Pierre A.
- ORCID
- Geoffroy, Pierre A.
- Palagini, Laura
- Henriksen, Tone E. G.
- Bourgin, Patrice
- Garbazza, Corrado
- Gronfier, Claude
- Esaki, Yuichi
- Fernandez, Diego C.
- Lam, Raymond W.
- Lee, Heon-Jeong
- Lejoyeux, Michel
- Maruani, Julia
- Martiny, Klaus
- Murray, Greg
- Ritter, Philipp
- Schulte, Peter F.J.
- Smith, Daniel J.
- Zeitzer, Jamie M.
- Sit, Dorothy K.
- Venue
- Dialogues in Clinical Neuroscience
- Publisher
- Informa UK Limited
- Published
- 2025-07-24
- Volume
- 27
- Issue
- 1
- Pages
- 249-264
- ISSN
- 1294-8322 (ISSN-L)
- 1958-5969
- PMC
- PMC12291220
- OpenAlex
- W4412623193
- Cited by
- 10
- References
- 97
- Citations by year
- 2026: 9 · 2025: 1
- FWCI
- 1.77
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Dialogues in Clinical Neuroscience (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
- HAL (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Circadian rhythm and melatonin
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- bright light therapy, bipolar disorder, bipolar depression, chronotherapy, chronobiology, relapse prevention, treatment response and remission, adjunctive therapy
- MeSH terms
- Bipolar Disorder, Chronobiology Phenomena, Circadian Rhythm, Humans, Phototherapy, Societies, Medical, Chronotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Light therapy for bipolar disorders: Clinical recommendations from the international society for bipolar disorders (ISBD) Chronobiology and Chronotherapy Task Force. https://app.cochat.ai/papers/10.1080/19585969.2025.2533806
- The paper
- Geoffroy, P. A., Palagini, L., Henriksen, T. E. G., Bourgin, P., Garbazza, C., Gronfier, C., Esaki, Y., Fernandez, D. C., Lam, R. W., Lee, H.-J., Lejoyeux, M., Maruani, J., Martiny, K., Murray, G., Riemersma-Van Der Lek, R. F., Ritter, P., Schulte, P. F. J., Smith, D. J., Terman, M., . . . Sit, D. K. (2025). Light therapy for bipolar disorders: Clinical recommendations from the international society for bipolar disorders (ISBD) Chronobiology and Chronotherapy Task Force. Dialogues in Clinical Neuroscience. https://doi.org/10.1080/19585969.2025.2533806
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.